Article

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System Database

2023-05-23

Abstract excerpt

<h4>Background: </h4> Although Two first-generation tropomyosin receptor kinase (TRK) inhibitors larotrectinib and entrectinib have been approved by the Food and Drug Administration (FDA), The current adverse effect profile in the real world remains unknown. <h4>Objective:</h4> The purpose of this study was to retrospectively examine the adverse effects of two typical first-generation TRK inhibitors by spontaneous...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8f83ca94-a43e-5d4d-a713-4ad942b09fa6
DOI: 10.22541/au.168485947.72029470/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseDOI 10.22541/au.168485947.72029470/v1Read

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Reported Drug Spectrum and Disproportionality Signals for Malignant Neoplasm Progression in FAERS: A Real-World Pharmacovigilance StudySemantic proximity Read

Safety assessment of S-1: Real-world adverse event analysis from the FAERS databaseSemantic proximity Read

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

Adverse event profile differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: a real-world, pharmacovigilance studySemantic proximity Read

Cutaneous adverse events associated with Rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024Semantic proximity Read

Real-World Data Analysis of Vascular and Lymphatic Adverse Events Associated with Anti-Tumor Angiogenesis Drugs: A WHO-VigiAccess StudySemantic proximity Read

Distinct Adverse Event Profiles of Eight Chemotherapeutic Agents: A FAERS Database Analysis Focusing on Peripheral NeuropathySemantic proximity Read

Analysis and Mining of Baloxavir Marboxil Adverse Event Signals in Elderly Patients Based on the FAERS DatabaseSemantic proximity Read

Delineating Drug Class and Target-Specific Adverse Events of Kinase InhibitorsSemantic proximity Read

Cross-Database Analysis of Fruquintinib-Associated adverse events: Insights from FAERS and VigiAccess databasesSemantic proximity Read